Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 786104, 11 pages
http://dx.doi.org/10.1155/2015/786104
Research Article

Ciclamilast Ameliorates Adjuvant-Induced Arthritis in a Rat Model

1College of Pharmaceutical Science, Zhejiang Chinese Medical University, No. 548 Binwen Road, Hangzhou 310053, China
2Department of Pharmacology, Zhejiang University School of Medicine, No. 866 Yuhangtang Road, Hangzhou 310058, China
3Laboratory Animal Center of Zhejiang University, Hangzhou 310058, China

Received 26 July 2014; Revised 23 September 2014; Accepted 25 September 2014

Academic Editor: Monica Fedele

Copyright © 2015 Zhi-cheng Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. Müller-Ladner, T. Pap, R. E. Gay, M. Neidhart, and S. Gay, “Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis,” Nature Clinical Practice: Rheumatology, vol. 1, no. 2, pp. 102–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Plasqui, “The role of physical activity in rheumatoid arthritis,” Physiology & Behavior, vol. 94, no. 2, pp. 270–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. E. Gabriel and K. Michaud, “Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases,” Arthritis Research and Therapy, vol. 11, no. 3, article 229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Singh, D. E. Furst, A. Bharat et al., “2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis,” Arthritis Care & Research, vol. 64, no. 5, pp. 625–639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Vivar and R. F. van Vollenhoven, “Advances in the treatment of rheumatoid arthritis,” F1000Prime Reports, vol. 6, article 31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Beghè, K. F. Rabe, and L. M. Fabbri, “Phosphodiesterase-4 inhibitor therapy for lung diseases,” The American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 3, pp. 271–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Kumar, A. M. Goldminz, N. Kim, and A. B. Gottlieb, “Phosphodiesterase 4-targeted treatments for autoimmune diseases,” BMC Medicine, vol. 11, no. 1, article 96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. F. E. McCann, A. C. Palfreeman, M. Andrews et al., “Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis,” Arthritis Research and Therapy, vol. 12, no. 3, article R107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Cush and Research Institute, “The controlled trial of Apremilast for rheumatoid arthritis treatment,” http://clinicaltrials.gov/show/NCT01250548.
  10. Y.-M. Deng, Q.-M. Xie, H.-F. Tang et al., “Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma,” European Journal of Pharmacology, vol. 547, no. 1–3, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. D. S. Fletcher, W. R. Widmer, S. Luell et al., “Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 284, no. 2, pp. 714–721, 1998. View at Google Scholar · View at Scopus
  12. C. J. Morris, “Carrageenan-induced paw edema in the rat and mouse,” Methods in Molecular Biology, vol. 225, pp. 115–121, 2003. View at Google Scholar · View at Scopus
  13. S. E. Ross, R. O. Williams, L. J. Mason et al., “Supression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by Rolipram,” Journal of Immunology, vol. 159, no. 12, pp. 6253–6259, 1997. View at Google Scholar · View at Scopus
  14. L. Sekut, D. Yarnall, S. A. Stimpson et al., “Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation,” Clinical & Experimental Immunology, vol. 100, no. 1, pp. 126–133, 1995. View at Google Scholar · View at Scopus
  15. U. Nyman, Å. Müssener, E. Larsson, J. Lorentzen, and L. Klareskog, “Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram,” Clinical and Experimental Immunology, vol. 108, no. 3, pp. 415–419, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. J. N. Francischi, C. M. Yokoro, S. Poole, W. L. Tafuri, F. Q. Cunha, and M. M. Teixeira, “Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis,” European Journal of Pharmacology, vol. 399, no. 2-3, pp. 243–249, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Y. Cho, J. S. Park, K. U. Baik et al., “Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevant to rheumatoid arthritis,” Pharmacological Research, vol. 49, no. 5, pp. 423–431, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hegen, J. C. Keith Jr., M. Collins, and C. L. Nickerson-Nutter, “Utility of animal models for identification of potential therapeutics for rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 11, pp. 1505–1515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Bendele, J. Mccomb, T. Gould et al., “Animal models of arthritis: relevance to human disease,” Toxicologic Pathology, vol. 27, no. 1, pp. 134–142, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. R. T. Owen, “Adjuvant induced polyarthritis—an overvieuw,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 2, no. 4, pp. 199–204, 1980. View at Google Scholar · View at Scopus
  21. F. C. Colpaert, T. Meert, P. de Witte, and P. Schmitt, “Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat,” Life Sciences, vol. 31, no. 1, pp. 67–75, 1982. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Ferraccioli, L. Bracci-Laudiero, S. Alivernini, E. Gremese, B. Tolusso, and F. de Benedetti, “Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis,” Molecular Medicine, vol. 16, no. 11-12, pp. 552–557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Kelly and M. Genovese, “Novel small molecule therapeutics in rheumatoid arthritis,” Rheumatology, vol. 52, no. 7, pp. 1155–1162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. G. D. Kersley, “Amethopterin (methotrexate) in connective tissue disease-psoriasis and polyarthritis.,” Annals of the Rheumatic Diseases, vol. 27, no. 1, pp. 64–66, 1968. View at Publisher · View at Google Scholar · View at Scopus
  25. M. E. Suarez-Almazor, E. Belseck, B. Shea, G. Wells, and P. Tugwell, “Methotrexate for rheumatoid arthritis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD000957, 2000. View at Google Scholar · View at Scopus
  26. J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar, “Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis,” Rheumatology, vol. 47, no. 3, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. L. Billingsley, N. Hall, and H. G. Mandel, “Trauma-induced glial proliferation: possible involvement of the immune system,” Immunopharmacology, vol. 5, no. 2, pp. 95–101, 1982. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Watanabe, S. Sato, S. Nagase, K. Shimosato, and S. Ohkuma, “Effects of methotrexate and cyclophosphamide on polyamine levels in various tissues of rats,” Journal of Drug Targeting, vol. 7, no. 3, pp. 197–205, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Feketeová, P. Jančová, P. Moravcová et al., “Effect of methotrexate on inflammatory cells redistribution in experimental adjuvant arthritis,” Rheumatology International, vol. 32, no. 11, pp. 3517–3523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Dogra and R. Mahajan, “Systemic methotrexate therapy for psoriasis: past, present and future,” Clinical and Experimental Dermatology, vol. 38, no. 6, pp. 573–588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. M. Yeo, V. H. Chong, A. Earnest, and W. L. Yang, “Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis,” World Journal of Hepatology, vol. 5, no. 5, pp. 275–280, 2013. View at Publisher · View at Google Scholar · View at Scopus